What is the address of Neurologie Dr C. Delwaide?

The registered office of Neurologie Dr C. Delwaide is located at Marche, Aux Bois d'en Bas 24, 6900 Marche-en-Famenne.

Is Neurologie Dr C. Delwaide still active?

Yes. According to the CBE (18 September 2026) Neurologie Dr C. Delwaide is active, legal situation “Normale toestand”, started on 7 January 2011.

Is Neurologie Dr C. Delwaide registered on Peppol?

No, Neurologie Dr C. Delwaide is currently not registered on the Peppol network.

What is the enterprise number of Neurologie Dr C. Delwaide?

The enterprise number of Neurologie Dr C. Delwaide is BE0832567727.

When was Neurologie Dr C. Delwaide founded?

Neurologie Dr C. Delwaide was founded on 7 January 2011.

Who are the directors of Neurologie Dr C. Delwaide?

According to the 2025 annual accounts, the directors of Neurologie Dr C. Delwaide are: Cécile DELWAIDE.

Is Neurologie Dr C. Delwaide a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 January 2011; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Neurologie Dr C. Delwaide make in 2025?

Neurologie Dr C. Delwaide recorded a loss after taxes of € 44,151 in financial year 2025.

What is the revenue of Neurologie Dr C. Delwaide?

As a small company, Neurologie Dr C. Delwaide is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -26,580.

Neurologie Dr C. Delwaide (Private Limited)

Dossier Neurologie Dr C. Delwaide, printed on 18 September 2026 from databakkes.be/en/0832567727/neurologie-dr-c-delwaide. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

Neurologie Dr C. Delwaide from Marche-en-Famenne, company number BE0832567727, closed financial year 2025 with a result of € -44,151 after tax. For that financial year Neurologie Dr C. Delwaide recorded a gross margin of € -26,580 and equity of € 618,008. Compared with financial year 2024, the result moved from € 132,900 to € -44,151. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 10, 2026.

What it is worth Healthy

€ 618,008

▼ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -44,151

▼ still € 132,900 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 567,395

▲ 7% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 605,608.

People and assets in 2025

Vehicles and equipment

€ 43,871

▼ 29% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 22,445

▼ 27% vs 2024

€ 8,743 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 163

▲ € 161 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,378

▼ 70% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 158,488 Gross margin 2022: € 158,488 First fiscal year in the series	€ 149,307 Gross margin 2023: € 149,307 ▼ 6% vs 2022 (€ 158,488) Unfavourable step	€ 198,320 Gross margin 2024: € 198,320 ▲ 33% vs 2023 (€ 149,307) Favourable step	€ -26,580 Gross margin 2025: € -26,580 ▼ € 224,900 vs 2024 (€ 198,320) Unfavourable step	▼ € 224,900
Profit after taxes	€ 100,449 Profit after taxes 2022: € 100,449 First fiscal year in the series	€ 94,780 Profit after taxes 2023: € 94,780 ▼ 6% vs 2022 (€ 100,449) Unfavourable step	€ 132,900 Profit after taxes 2024: € 132,900 ▲ 40% vs 2023 (€ 94,780) Favourable step	€ -44,151 Profit after taxes 2025: € -44,151 ▼ € 177,051 vs 2024 (€ 132,900) Unfavourable step	▼ € 177,051
Equity	€ 585,744 Equity 2022: € 585,744 First fiscal year in the series	€ 589,257 Equity 2023: € 589,257 ▲ 1% vs 2022 (€ 585,744) Favourable step	€ 662,159 Equity 2024: € 662,159 ▲ 12% vs 2023 (€ 589,257) Favourable step	€ 618,008 Equity 2025: € 618,008 ▼ 7% vs 2024 (€ 662,159) Unfavourable step	▼ 7%
Total debts	€ 33,286 Total debts 2022: € 33,286 First fiscal year in the series	€ 17,567 Total debts 2023: € 17,567 ▼ 47% vs 2022 (€ 33,286) Favourable step	€ 43,019 Total debts 2024: € 43,019 ▲ 145% vs 2023 (€ 17,567) Unfavourable step	€ 26,812 Total debts 2025: € 26,812 ▼ 38% vs 2024 (€ 43,019) Favourable step	▼ 38%
Cash	€ 460,572 Cash 2022: € 460,572 First fiscal year in the series	€ 438,929 Cash 2023: € 438,929 ▼ 5% vs 2022 (€ 460,572) Unfavourable step	€ 528,243 Cash 2024: € 528,243 ▲ 20% vs 2023 (€ 438,929) Favourable step	€ 567,395 Cash 2025: € 567,395 ▲ 7% vs 2024 (€ 528,243) Favourable step	▲ 7%
Retained profit	€ 573,344 Retained profit 2022: € 573,344 First fiscal year in the series	€ 576,857 Retained profit 2023: € 576,857 ▲ 1% vs 2022 (€ 573,344) Favourable step	€ 649,759 Retained profit 2024: € 649,759 ▲ 13% vs 2023 (€ 576,857) Favourable step	€ 605,608 Retained profit 2025: € 605,608 ▼ 7% vs 2024 (€ 649,759) Unfavourable step	▼ 7%
Dividend	€ 75,825 Dividend 2022: € 75,825 First fiscal year in the series	€ 91,267 Dividend 2023: € 91,267 ▲ 20% vs 2022 (€ 75,825) Unchanged	€ 59,997 Dividend 2024: € 59,997 ▼ 34% vs 2023 (€ 91,267) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 59,997) Unchanged	▼ 100%
Bank debt	€ 11,792 Bank debt 2022: € 11,792 First fiscal year in the series	€ 3,953 Bank debt 2023: € 3,953 ▼ 66% vs 2022 (€ 11,792) Favourable step	€ 30,888 Bank debt 2024: € 30,888 ▲ € 26,934 vs 2023 (€ 3,953) Unfavourable step	€ 22,445 Bank debt 2025: € 22,445 ▼ 27% vs 2024 (€ 30,888) Favourable step	▼ 27%
Balance sheet total	€ 619,030 Balance sheet total 2022: € 619,030 First fiscal year in the series	€ 606,824 Balance sheet total 2023: € 606,824 ▼ 2% vs 2022 (€ 619,030) Unchanged	€ 705,178 Balance sheet total 2024: € 705,178 ▲ 16% vs 2023 (€ 606,824) Unchanged	€ 644,820 Balance sheet total 2025: € 644,820 ▼ 9% vs 2024 (€ 705,178) Unchanged	▼ 9%

Key figures of Neurologie Dr C. Delwaide, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Neurologie Dr C. Delwaide?

What happened at Neurologie Dr C. Delwaide in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 10, 2026 New annual accounts for financial year 2025: loss of € 44,151 (▼ € 177,051 vs 2024). Source: NBB ↗
Jan 7, 2011 New establishment in Marche-en-Famenne. KBO
2011 Cécile DELWAIDE became a director. NBB
Jan 7, 2011 Start of the company according to the CBE. KBO

In short

From € 100,449 profit in 2022 to € 44,151 loss in 2025.

Paid € 136,240 in corporate taxes since 2022.

Best year ever: 2024, with € 132,900 profit.

Paid out € 227,089 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Neurologie Dr C. Delwaide? We notify you, reason included.

Follow Neurologie Dr C. Delwaide

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Cécile DELWAIDE

Neurologie Dr C. Delwaide

Behind Neurologie Dr C. Delwaide is Cécile DELWAIDE.

See the full network in the app

Directors

According to the 2025 annual accounts

Cécile DELWAIDE

Director

since 2011

Establishments

Establishment units

Physical locations of this company

Registered office

Marche, Aux Bois d'en Bas 24

6900 Marche-en-Famenne

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0832.567.727
VAT number: BE 0832.567.727
Registered office: Marche, Aux Bois d'en Bas 24, 6900 Marche-en-Famenne
Names & denominations: Neurologie Dr C. Delwaide
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 7 January 2011
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗